← Back to Screener
Neumora Therapeutics, Inc. Common Stock (NMRA)
Price$1.63
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-35.16%
Price vs S&P 500 (4W)-10.92%
VGM Score45.00
Market Capitalization$302.01M
All Metrics
Book Value / Share (Quarterly)$0.39
P/TBV (Annual)4.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.06
Price vs S&P 500 (YTD)-17.10%
EPS (TTM)$-1.33
10-Day Avg Trading Volume0.94M
EPS Excl Extra (TTM)$-1.33
EPS (Annual)$-1.45
ROI (Annual)-149.57%
Cash / Share (Quarterly)$0.81
ROA (Last FY)-124.02%
EBITD / Share (TTM)$-1.33
ROE (5Y Avg)-90.99%
Cash Flow / Share (Annual)$-1.18
P/B Ratio4.27x
P/B Ratio (Quarterly)5.02x
Net Income / Employee (Annual)$-2,468,000
ROA (TTM)-119.15%
EPS Incl Extra (Annual)$-1.45
Current Ratio (Annual)5.87x
Quick Ratio (Quarterly)4.88x
3-Month Avg Trading Volume1.31M
52-Week Price Return101.21%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.36
52-Week High$3.65
EPS Excl Extra (Annual)$-1.45
26-Week Price Return-27.23%
Quick Ratio (Annual)5.62x
13-Week Price Return-45.67%
Total Debt / Equity (Annual)0.53x
Current Ratio (Quarterly)5.09x
Enterprise Value$207.90M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.05
3-Month Return Std Dev79.19%
Net Income / Employee (TTM)$-2,316,600
ROE (Last FY)-228.10%
EPS Basic Excl Extra (Annual)$-1.45
Total Debt / Equity (Quarterly)0.75x
EPS Incl Extra (TTM)$-1.33
ROI (TTM)-139.85%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.61
Price vs S&P 500 (52W)76.84%
Year-to-Date Return-8.94%
5-Day Price Return-10.44%
EPS Normalized (Annual)$-1.45
ROA (5Y Avg)-66.89%
Month-to-Date Return-11.89%
EBITD / Share (Annual)$-1.47
LT Debt / Equity (Annual)0.53x
ROI (5Y Avg)-75.29%
LT Debt / Equity (Quarterly)0.75x
EPS Basic Excl Extra (TTM)$-1.33
P/TBV (Quarterly)3.53x
P/B Ratio (Annual)2.88x
Book Value / Share (Annual)$0.60
Price vs S&P 500 (13W)-53.92%
Beta2.86x
Revenue / Share (TTM)$0.00
ROE (TTM)-181.70%
52-Week Low$0.72
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.30est. -0.32
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.07
4.07
4.07
4.07
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NMRANeumora Therapeutics, Inc. Common Stock | — | — | C | $1.63 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for neuropsychiatric and neurodegenerative diseases. Its pipeline consists of seven clinical and preclinical programs targeting new mechanisms of action in underserved areas of neuroscience. The company aims to address significant unmet medical needs through its differentiated approach to brain disease treatment.